December 10, 2019 – The ASCO Post

Caroline Helwick  / December 10, 2019 In patients with relapsed or refractory multiple myeloma, the addition of daratumumab to carfilzomib plus dexamethasone improved multiple outcomes, compared with carfilzomib/dexamethasone alone, in the international phase III CANDOR trial.1 “Overall,…

Read the full article here

Related Articles